Skip to main content
SpringerLink
Log in

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349–353.

    PubMed  Google Scholar 

  2. Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2615–2622.

    PubMed  Google Scholar 

  3. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366–370.

    PubMed  Google Scholar 

  4. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471–2476.

    PubMed  Google Scholar 

  5. National Committee for Clinical Laboratory Standards: Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. NCCLS, Villanova, PA, 1993.

    Google Scholar 

  6. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A5. NCCLS, Villanova, PA, 1993.

    Google Scholar 

  7. Metzler CM, DeHaan RM: Susceptibility of anaerobic bacteria: statistical and clinical considerations. Journal of Infectious Diseases 1979, 130: 588–596.

    Google Scholar 

  8. Jones RN: Preliminary interpretive criteria for in vitro susceptibility testing of CP-99,219 by dilution and disk diffusion methods. Diagnostic Microbiology and Infectious Disease 1994, 20: 167–170.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Clinical Microbiology Institute, PO Box 947, 97062, Tualatin, Oregon, USA

    P. C. Fuchs, A. L. Barry & S. D. Brown

  2. Veterans Affairs Medical Center, 97201, Portland, Oregon, USA

    D. L. Sewell

Authors
  1. P. C. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. L. Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. L. Sewell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fuchs, P.C., Barry, A.L., Brown, S.D. et al. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 15, 678–682 (1996). https://doi.org/10.1007/BF01691159

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01691159

Keywords

Search

Navigation